Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug ...

Bioinformaticians have now developed a unique method with which all metabolites in a sample can be taken into account, thus considerably increasing the knowledge gained from examining such molecules.

The new programme addresses the urgent unmet medical need for new therapies to tackle antibiotic-resistant infections ...

A new non-addictive class of compounds developed by researchers at Purdue’s College of Pharmacy could lead to the treatment of chronic pain conditions, such as back pain and arthritis, in the absence ...

Using a type of artificial intelligence known as deep learning, MIT researchers have discovered a class of compounds that can kill a drug-resistant bacterium that causes more than 10,000 deaths in the ...

Biotech partner would develop Enveric's three classes of compounds from its AI-powered drug discovery platform. Licensee to receive exclusive global licenses to develop and sublicense the three assets ...

—RX-04 compounds also demonstrate potent in vivo activity against the deadly superbug, Klebsiella pneumoniae, including against carbapenem- and colistin-resistant strains — Rib-X Pharmaceuticals, Inc.

Scientists at Uppsala University have discovered a new class of antibiotics with potent activity against multi-drug resistant (MDR) Gram-negative bacteria. The new compounds target a protein, LpxH, ...

Researchers have shown, in mice, that a new class of compounds they developed can improve several aspects of metabolic syndrome. Such conditions often lead to cardiovascular disease, the leading cause ...